A Phase II, Single Arm, Open Label Study of Treatment-free Remission in Chronic Myeloid Leukemia (CML) Chronic Phase (CP) Patients After Achieving Sustained MR4.5 on Nilotinib
A clinical research study to find out if it is safe to stop the drug nilotinib (Tasigna) in
chronic myeloid leukemia (CML) patients. Patients who started treatment with imatinib
(Gleevec) when they were first diagnosed with CML, then switched to nilotinib (Tasigna) for
at least 2 years with the combined time on imatinib (Gleevec) and nilotinib (Tasigna) for at
least 3 years and have very small amount of leukemia cells remaining after the nilotinib
(Tasigna) treatment will qualify for the study.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society